Sterotherapeutics LLC
Sterotherapeutics LLC
Categories
Pharmaceutical
About
SteroTherapeutics is pursuing a novel drug therapy for Non-alcoholic steatohepatitis (NASH) which has been predicted as the next major health epidemic. The situation is paramount as NASH has no approved treatments and is a leading cause of liver related morbidity and mortality. Analysts are forecasting that the market for NASH treatment could reach $35-$40 Billion by 2025.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.